Lidoderm and Extrapyramidal disorder - a phase IV clinical study of FDA data

Summary:

Extrapyramidal disorder is reported as a side effect among people who take Lidoderm (lidocaine), especially for people who are female, 60+ old, also take Metoclopramide, and have Gastroesophageal reflux disease.

The phase IV clinical study analyzes which people have Extrapyramidal disorder when taking Lidoderm. It is created by eHealthMe based on reports of 10,321 people who have side effects when taking Lidoderm from the FDA, and is updated regularly.

What is Lidoderm?

Lidoderm has active ingredients of lidocaine. It is often used in pain. eHealthMe is studying from 10,524 Lidoderm users. Check the latest studies of Lidoderm.

What is Extrapyramidal disorder?

Extrapyramidal disorder (involuntary muscle spasms in the face and neck) is found to be associated with 813 drugs and 960 conditions by eHealthMe. Check the latest studies of Extrapyramidal disorder.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 16, 2026

10,321 people reported to have side effects when taking Lidoderm.
Among them, 19 people (0.18%) have Extrapyramidal disorder.

Could Lidoderm cause Extrapyramidal disorder?

Among these 19 people:

What is the gender of people who have Extrapyramidal disorder when taking Lidoderm? *

female: 88.24 %
male: 11.76 %

What is the age of people who have Extrapyramidal disorder when taking Lidoderm? *

What are other drugs people take besides Lidoderm? *

What are other side effects people have besides Extrapyramidal disorder? *

Tardive Dyskinesia (a disorder that involves involuntary movements): 18 people, 94.74%
Tremor (trembling or shaking movements in one or more parts of your body): 12 people, 63.16%
Emotional Disorder: 10 people, 52.63%
Emotional Distress: 9 people, 47.37%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 8 people, 42.11%
Depression: 8 people, 42.11%
Movement - Uncontrolled Or Slow: 8 people, 42.11%
Insomnia (sleeplessness): 8 people, 42.11%
Injury: 8 people, 42.11%
Stress And Anxiety: 8 people, 42.11%

What are the existing conditions these people have? *

Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 6 people, 31.58%
Impaired Gastric Emptying: 3 people, 15.79%
Nausea (feeling of having an urge to vomit): 2 people, 10.53%
Indigestion: 2 people, 10.53%
Hiatal Hernia (hernia resulting from the protrusion of part of the stomach through the diaphragm): 2 people, 10.53%
Reflux Gastritis (a condition in which the lining of a person's stomach becomes inflamed as a result of exposure to bile): 1 person, 5.26%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 5.26%
Irritable Bowel Syndrome: 1 person, 5.26%
Gastric Ulcer (stomach ulcer): 1 person, 5.26%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Lidoderm and have Extrapyramidal disorder?

- Check whether Extrapyramidal disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lidoderm:

Lidoderm (10,524 reports)

Browse all side effects of Lidoderm:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Extrapyramidal disorder:

Extrapyramidal disorder (813 drugs)

Browse all the conditions that are associated with Extrapyramidal disorder:

Extrapyramidal disorder (960 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on lidocaine (the active ingredients of Lidoderm) and Lidoderm (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.